Category: Asean

Domestic Recovery Surges While International Capacity Nears Pre-Pandemic Levels

Key takeaways:

• Total capacity surpasses pre-pandemic levels up 0.5% on 2019.
• Domestic market outperforms 2019 up 4.7% on 2019; China and India lead the way.
• Competitive pricing drives up to 71% reduction in average ticket prices.

SINGAPORE, Feb. 17, 2025 (GLOBE NEWSWIRE) — Latest analysis from leading travel data provider, OAG, confirms that the Asia-Pacific (ASPAC) region is on track to solidify its position as the world’s most competitive aviation market in 2025, having surpassed 2019’s total capacity by 0.5% in 2024. Both domestic and international sectors show remarkable growth and resilience.

OAG’s latest report ‘Is Asia Pacific the World’s Most Competitive Aviation Market?’ reveals how domestic markets across the region have rebounded strongly, now operating at 4.7% above 2019 levels. This growth underscores the critical role of domestic travel in driving the region’s aviation recovery.

Chinese domestic capacity is now 14% above 2019, and India is 13% ahead of pre-pandemic levels. These two countries, along with Japan and Indonesia, boast more than 100 million seats in their domestic markets.
However, Japan remains 4% behind 2019 domestic capacity levels as a combination of socio-economic factors hold back growth. Contributing to Indonesia’s slower return (17% behind) are ongoing supply chain issues, with 27% of the country’s aircraft currently stored or out for maintenance.

On the international front, the ASPAC region has achieved 594.8 million seats, making it the second-largest international aviation market globally. While this figure is below 2019 levels, ASPAC now accounts for one in every four international seats worldwide.

Leading the charge in international seat capacity are Singapore Airlines, Cathay Pacific, and China Eastern. Singapore Airlines is also among the three Asia Pacific airlines within the top 10 for international capacity that have surpassed their 2019 levels, with 14.1% more than in 2024. The other two are Scoot (+13.8%) and EVA Airways (+4.5%).

The report also explains how airfares in the region have been driven down by rapid capacity expansion and increased competition. Average ticket prices on 17 of the 20 largest growth markets have declined, many by more than 20%, with Bangkok to Shanghai Pudong (BKK-PVG) seeing a 71% reduction in fares, year on year.

OAG’s Head of Asia Pacific, Mayur Patel commented:

“As the Asia Pacific region continues to expand, the synergy of robust domestic recovery, dynamic international growth, and competitive strategic pricing makes it the world’s most vibrant and competitive aviation market.”

Read OAG’s report, “Is Asia Pacific the Most Competitive Aviation Market?” on their website.

About OAG
OAG is a leading data platform for the global travel industry offering an industry-first single source for supply, demand, and pricing data.

Media Enquiries: [email protected]

For more information on OAG visit www.oag.com.

GlobeNewswire Distribution ID 9359452

First in market to offer Adjustable Tensioning Technology* for insertional Achilles reconstruction and lateral ankle instability repair

*After anchor insertion

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of a comprehensive foot & ankle repair portfolio in Australia and New Zealand (ANZ) with proprietary adjustable tensioning technology. The ULTRABRIDGE^◊ Adjustable Achilles Reconstruction and ULTRABRACE^◊ Adjustable Ankle Instability Techniques are changing the way foot & ankle surgeons perform these repairs by allowing them to refine and optimise suture tension after anchor insertion.

The ability to adjust tension for specific patients allows the surgeon to give the precise amount of range-of-motion to that patient depending on the patient’s level of activity. The surgeon can check and revise the repair construct before locking the suture, which may help restore normal anatomy and deliver potentially better outcomes for the patient.

The new foot & ankle portfolio also includes Smith+Nephew’s best-in-class all suture anchor with consistent deployment and strong fixation, now integrated with needles for open procedures. The anchor inserter tensions the device on deployment, ensuring consistency every time.

“Both Australians and New Zealanders are very physically active, with sports and active recreation participation rates exceeding 75%.¹ Our portfolio of foot & ankle solutions represents a truly groundbreaking introduction for today’s athletes by offering adjustable tensioning technology after anchor insertion, which is not currently available in the ANZ market,” said Mr. Joaquin Lasso, SVP of Sports Medicine, International Markets for Smith+Nephew. “This technology allows surgeons to personalise their treatment for each patient and returns them to living their Life Unlimited.”

Each year, around 230,000 Australians see a General Practitioner for an ankle sprain or strain.² To learn more about Smith+Nephew’s global foot & ankle solutions please visit here.

– ends –

Media Enquiries

Dave Snyder          +1 (978) 749-1440

Smith+Nephew      [email protected]

References

• We Reveal The World’s Sportiest Countries | Which Nation Will Take First Place? – MYPROTEIN
• NPS MedicineWise Ankle sprains: 10 things you should know

 About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.

^◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

GlobeNewswire Distribution ID 1001048648